达沙替尼联合纳武单抗用于既往治疗过的慢性髓性白血病患者的安全性和疗效：1b期剂量递增研究结果 - Suppr | 超能文献

相似文献

1

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study.达沙替尼联合纳武单抗用于既往治疗过的慢性髓性白血病患者的安全性和疗效：1b期剂量递增研究结果

Leuk Lymphoma. 2021 Aug;62(8):2040-2043. doi: 10.1080/10428194.2021.1889536. Epub 2021 Mar 2.

2

Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia.对达沙替尼在慢性髓性白血病真实世界患者中的应用及疗效的见解。

Haematologica. 2023 Aug 1;108(8):2224-2228. doi: 10.3324/haematol.2022.282237.

3

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.达沙替尼治疗慢性髓性白血病后的淋巴细胞增多：对反应和毒性的影响。

Cancer. 2016 May 1;122(9):1398-407. doi: 10.1002/cncr.29933. Epub 2016 Mar 21.

4

Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?对于新诊断的慢性期慢性髓性白血病患者，50毫克/天是达沙替尼的新标准剂量吗？

Expert Rev Hematol. 2024 Jul;17(7):275-277. doi: 10.1080/17474086.2024.2370556. Epub 2024 Jun 25.

5

Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.一线达沙替尼治疗新诊断慢性期慢性髓性白血病的临床疗效与安全性以及BCR-ABL1转录本下降速度与实现分子反应的相关性：顺天堂山梨合作研究组报告

Oncology. 2018;94(2):85-91. doi: 10.1159/000481945. Epub 2017 Nov 18.

6

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.达沙替尼用于对伊马替尼耐药或不耐受的慢性期慢性髓性白血病患者：CA180-034研究的7年随访

Am J Hematol. 2016 Sep;91(9):869-74. doi: 10.1002/ajh.24423. Epub 2016 Jun 20.

7

[Efficacy and safety of domestic dasatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase].国产达沙替尼治疗初诊慢性期慢性髓性白血病患者的疗效与安全性

Zhonghua Xue Ye Xue Za Zhi. 2020 Apr 14;41(4):318-321. doi: 10.3760/cma.j.issn.0253-2727.2020.04.011.

8

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.达沙替尼治疗伊马替尼耐药/不耐受的慢性期慢性髓性白血病患者的长期疗效在日常临床实践中是有利的。

Leuk Lymphoma. 2021 Jan;62(1):194-202. doi: 10.1080/10428194.2020.1827242. Epub 2020 Oct 6.

9

Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.低剂量达沙替尼 50mg/天与标准剂量达沙替尼 100mg/天作为慢性髓性白血病慢性期一线治疗的比较：倾向评分分析。

Am J Hematol. 2022 Nov;97(11):1413-1418. doi: 10.1002/ajh.26689. Epub 2022 Aug 27.

10

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.慢性期慢性髓性白血病伊马替尼不耐受患者中对达沙替尼的交叉不耐受

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):341-349.e1. doi: 10.1016/j.clml.2016.03.004. Epub 2016 Mar 29.

引用本文的文献

1

Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.博舒替尼与阿特珠单抗联合治疗慢性髓性白血病患者的肝毒性：ZEROLMC 研究结果。

Ann Hematol. 2024 Oct;103(10):4045-4055. doi: 10.1007/s00277-024-05662-7. Epub 2024 Apr 3.

2

Progress of research on PD-1/PD-L1 in leukemia.PD-1/PD-L1 在白血病中研究进展。

Front Immunol. 2023 Sep 26;14:1265299. doi: 10.3389/fimmu.2023.1265299. eCollection 2023.

3

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.